Junshi narrows its losses but delivers no cure for share price woes
The drug maker boosted sales of its core anti-cancer product in the first half of the year and reined in its research budget under a reform-minded CEO, but revenue momentum…
FAST NEWS: Innovent Bio’s loss narrows on strong sales growth
The latest: Biotech company Innovent Biologics Inc. (1801.HK) announced Wednesday its annual net loss last year narrowed 52.8% year-over-year to 1.03 billion yuan ($143 million), while its non-GAAP net narrowed by an even…
Junshi hopes new scientist CEO can cure its woes
The biotech company has been dogged by multiple challenges recently, including declining revenue, ongoing losses and a recent rejection by one of its overseas partners Key Takeaways: Junshi has appointed…
Will Junshi Bio’s loss-making headaches ease with landmark U.S. drug approval?
The FDA has given the nod to the Chinese company’s PD-1 drug, but most of the benefits will go to a third-party licensee Key Takeaways: Junshi Bio will receive milestone…
FAST NEWS: Innovent Bio’s revenue soars on strong cancer treatment sales
The latest: Biotech company Innovent Biologics Inc. (1801.HK) announced on Thursday it recorded product revenue of more than 1.6 billion yuan ($2.2 million) in the third quarter, up 45% year-on-year, and also…
FAST NEWS: Innovent Bio to raise HK$2.4 billion in share placement
The latest: Biotech company Innovent Biologics Inc. (1801.HK) announced on Tuesday it will place 68 million new shares, representing approximately 4.22% of its enlarged share capital, to raise about HK$2.36 billion ($302 million).…
Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas
Cancer drug maker ended a tie-up to bring one of its drugs to North America last week, less than two months after its best-selling product was rejected by the FDA…
